These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34034278)

  • 1. Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece.
    Gatopoulou A; Christodoulou DK; Katsanos KH; Bakos D; Mouzas I; Tzouvala M; Theodoropoulou A; Paspatis G; Theocharis G; Thomopoulos K; Giouleme O; Kourikou A; Manolakopoulos S; Zampeli E; Michopoulos S; Karatzas P; Katsaros M; Moschovis D; Orfanoudaki E; Livieratos A; Petrikkou E; Mantzaris GJ
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e615-e624. PubMed ID: 34034278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.
    Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S
    BMC Gastroenterol; 2021 Apr; 21(1):161. PubMed ID: 33845784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results.
    Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S
    World J Gastroenterol; 2020 Jun; 26(21):2852-2863. PubMed ID: 32550760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study.
    Psaltis D; Settas L; Georgiadis A; Koukli E; Bounas A; Livieratos A; Petrikkou E; Kalogiannaki H; Repa A; Vassilopoulos D; Sidiropoulos P
    Rheumatol Int; 2022 Apr; 42(4):639-650. PubMed ID: 35091757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
    Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
    World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).
    Probert CS; Sebastian S; Gaya DR; Hamlin PJ; Gillespie G; Rose A; Tate H; Wheeler C; Irving PM
    BMJ Open Gastroenterol; 2018; 5(1):e000212. PubMed ID: 30002864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study.
    Gibson PR; Vaizey C; Black CM; Nicholls R; Weston AR; Bampton P; Sparrow M; Lawrance IC; Selby WS; Andrews JM; Walsh AJ; Hetzel DJ; Macrae FA; Moore GT; Weltman MD; Leong RW; Fan T
    J Crohns Colitis; 2014 Jul; 8(7):598-606. PubMed ID: 24345767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.
    Ferrante M; Schirbel A; Pierik MJ; Haas T; Flamant M; Khalifa A; Philip G; Cornillie F; Meehan AG; Govoni M
    Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):646-654. PubMed ID: 35412484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study.
    Saibeni S; Bezzio C; Bossa F; Privitera AC; Marchi S; Roselli J; Mazzuoli S; Geccherle A; Soriano A; Principi MB; Viola A; Sarpi L; Cappello M; D'Incà R; Mastronardi M; Bodini G; Guerra M; Benedetti A; Romano M; Cicala M; Di Sabatino A; Scaldaferri F; De Rosa T; Giardino AM; Germano V; Orlando A; Armuzzi A
    Dig Liver Dis; 2024 Jan; 56(1):83-91. PubMed ID: 37574431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study.
    Bessissow T; Nguyen GC; Tarabain O; Peyrin-Biroulet L; Foucault N; McHugh K; Ruel J
    World J Gastroenterol; 2022 Sep; 28(34):5058-5075. PubMed ID: 36160646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
    Taxonera C; Rodríguez C; Bertoletti F; Menchén L; Arribas J; Sierra M; Arias L; Martínez-Montiel P; Juan A; Iglesias E; Algaba A; Manceñido N; Rivero M; Barreiro-de Acosta M; López-Serrano P; Argüelles-Arias F; Gutierrez A; Busquets D; Gisbert JP; Olivares D; Calvo M; Alba C;
    Inflamm Bowel Dis; 2017 Aug; 23(8):1394-1402. PubMed ID: 28671873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain.
    Targownik L; Dubinsky MC; Steinwurz F; Bushmakin AG; Cappelleri JC; Tai E; Gardiner S; Hur P; Panés J
    J Crohns Colitis; 2023 Apr; 17(4):513-523. PubMed ID: 36271912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
    Armuzzi A; Rubin DT; Schreiber S; Panés J; Fellmann M; Bartolome L; Gruben D; Goetsch M; Bhattacharjee A; Chaparro M; Dubinsky MC
    Inflamm Bowel Dis; 2024 Sep; ():. PubMed ID: 39326009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe.
    Armuzzi A; Tarallo M; Lucas J; Bluff D; Hoskin B; Bargo D; Cappelleri JC; Salese L; daCosta DiBonaventura M
    BMC Gastroenterol; 2020 Jan; 20(1):18. PubMed ID: 31964359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence.
    Olivera P; Danese S; Pouillon L; Bonovas S; Peyrin-Biroulet L
    Dig Liver Dis; 2019 Mar; 51(3):327-334. PubMed ID: 30555013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
    O'Connell J; Rowan C; Stack R; Harkin G; Parihar V; Chan G; Breslin N; Cullen G; Dunne C; Egan L; Harewood G; Leyden J; MacCarthy F; MacMathuna P; Mahmud N; McKiernan S; McNamara D; Mulcahy H; Murray F; O'Connor A; O'Toole A; Patchett S; Ryan B; Sheridan J; Slattery E; Doherty G; Kevans D
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1019-1026. PubMed ID: 29878945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.
    Taxonera C; Iborra M; Bosca-Watts MM; Rubio S; Nantes Ó; Higuera R; Bertoletti F; Martínez-Montiel P; Sierra-Ausin M; Manceñido N; Lázaro Pérez-Calle J; Algaba A; Olivares D; Alba C
    Curr Med Res Opin; 2019 Jul; 35(7):1297-1304. PubMed ID: 30722703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.